Increased ErbB2 Signaling Is an Early Adaptation to Androgen Signaling Inhibition and Persists in Castration-Resistant Prostate Cancer
Increased ErbB2 signaling is a rapid adaptation to ASI and contributes to castration resistance. Increases in NRG1 and d16ERBB2 contribute to increased ErbB2 signaling. Potent ErbB2 antagonists may enhance responses to ASI in castration-sensitive prostate cancer, and ErbB2 phosphorylation may be a biomarker for tumors that will respond in CRPC.
Authors
- Mary‐Ellen Taplin (ORCID: https://orcid.org/0000-0002-3384-0300)
- William J. Muller (ORCID: https://orcid.org/0000-0002-7293-4166)
- Jude Owiredu (ORCID: https://orcid.org/0000-0002-7361-501X)
- Charlene Mantia (ORCID: https://orcid.org/0000-0001-7672-3131)
- David Johnson Einstein (ORCID: https://orcid.org/0000-0001-9163-3281)
- Fang Xie (ORCID: https://orcid.org/0000-0002-6121-0875)
- Olga Voznesensky (ORCID: https://orcid.org/0000-0003-1033-0938)
- Christopher M. Dennehy (ORCID: https://orcid.org/0009-0007-5178-0915)
- Huihui Ye (ORCID: https://orcid.org/0000-0002-8307-9492)
- Joshua W. Russo (ORCID: https://orcid.org/0000-0001-5481-0090)
- Carla Calagua (ORCID: https://orcid.org/0000-0003-4438-8046)
- Larysa Poluben (ORCID: https://orcid.org/0000-0002-5433-6963)
- Yue Sun (ORCID: https://orcid.org/0009-0007-4499-5221)
- Steven P. Balk (ORCID: https://orcid.org/0000-0002-4546-7371)
- Betul Ersoy-Fazlioglu (ORCID: https://orcid.org/0000-0002-9410-3427)
- Anastasia-Maria Stavridi (ORCID: https://orcid.org/0009-0006-2817-3853)
- Xin Gao (ORCID: https://orcid.org/0009-0008-2346-068X)
- Liyang Wang (ORCID: https://orcid.org/0009-0007-5252-8092)
Institutions
- Cedars-Sinai Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- Mount Sinai Hospital (US)
- Cornell University (US)
- McGill University Health Centre (CA)
- Harvard University Press (US)
- Massachusetts General Hospital (US)
- Mount Sinai Medical Center (US)
- Mount Sinai Hospital (US)
- Dana-Farber Cancer Institute (US)
- McGill University (CA)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-08-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-22-3683
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Prostate Cancer Foundation
- Bristol-Myers Squibb
- Puma Biotechnology
- Foundation Medicine